Fail Faster: How Biopharma Companies Can Capitalize on Early Drug Development Failures
It typically takes 10 to 15 years to develop a new drug therapy, conduct clinical trials, and pass regulatory requirements. What’s more, only 9.6% of the drugs that enter clinical trials are approved by the Food and Drug Administration. In short, drug developers are facing an uphill battle as they seek to accelerate product development and improve clinical outcomes.
The methodology of “fail fast” focuses on spotting potential dead-ends early in the drug development cycle to reduce R&D costs, improve clinical outcomes, and speed time to market. The fail fast methodology is particularly important for small and medium-sized enterprises (SMEs) in the biopharmaceutical market who must be extremely resourceful on sometimes limited budgets. Therefore, 'failing faster' and recognizing potential pitfalls early on - ahead of costly clinical trials - becomes ever more critical.
Join us for a complimentary webinar where you'll hear from a panel of experts in biopharma discovery, R&D, and clinical trial design as they discuss the benefits and challenges of a fail fast strategy. Representatives from companies that have successfully adopted this innovative approach will participate as well, offering valuable insights on what worked—and what did not.
When to implement 'fail fast' for maximum cost savings
How to use 'fail fast' tactics to validate drug targets
Where to shift your R&D strategies for optimal success
Andrew A. Radin Co-founder and Chief Executive Officer Aria Pharmaceuticals
Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging Pharma Leader by Pharma Executive magazine, was invited to give a TEDMED talk, and was named a Top 100 AI Leader by Deep Knowledge Analytics. In addition to his duties as CEO at Aria, Andrew serves as an advisor to Stanford University’s SPARK drug development and Stanford University’s StartX startup accelerator programs. Prior to co-founding Aria, Andrew served as Chief Technology Officer at several successful internet startups. His prior projects have reached tens of millions of people in telephony systems, advertising networks, video games, and geographical mapping systems. Andrew studied Biomedical Informatics at Stanford University’s SCPD graduate program and holds a Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
Nader Sanai, MD Director of the Ivy Brain Tumor Center J.N. Harber Professor of Neurological Surgery The Barrow Neurological Institute
Nader Sanai, MD is the J.N. Harber Professor of Neurological Surgery at the Barrow Neurological Institute. His specialty neurosurgical practice is devoted to patients with benign and malignant brain tumors, particularly those in high-risk areas. He is a renowned expert in brain mapping techniques to identify and preserve areas of motor, sensory, and language function during surgery. As one of the nation’s highest-volume neurosurgical oncologists, Dr. Sanai was elected to the American Academy of Neurological Surgeons in 2016. In 2018, he founded and now directs the Ivy Brain Tumor Center, a not-for-profit drug development program specializing in Phase 0 trials and other pharmacokinetic- and pharmacodynamic-driven studies for brain tumors. Dr. Sanai has authored more than 200 peer-reviewed publications and delivered over 100 national and international lectures in neuro-oncology.
Shane Hunt Chief Customer Success Officer Research Solutions
Shane provides leadership resulting in the development of healthy long-term relationships with the Company’s cloud-based software customers, and ensures the daily satisfaction of users across R&D-driven organizations in life sciences, technology and academia worldwide.
He has nearly 20 years of industry experience and was co-founder of 4 Research Solutions Inc., a boutique information industry start-up that the Company acquired in 2012. Shane attended California State University, Chico for his undergraduate and graduate studies in Psychology. In his personal time, he enjoys spending time with his family and coaching youth sports.